Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States

Abstract

Telavancin had MIC 50 , MIC 90 , and MIC 100 values of 0.03, 0.06, and 0.12 g/ml, respectively, against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), and non-multidrug-resistant (non-MDR) and MDR subsets. MRSA with elevated MIC values for vancomycin (2 to 4 g/ml) or daptomycin (1 to 2 g/ml) had telavancin MIC 50 (0.06 g/ml) values 2-fold higher than those of isolates with lower MIC results (MIC 50 , 0.03 g/ml). However, telavancin had MIC 90 and MIC 100 results of 0.06 and 0.12 g/ml (100% susceptible), respectively, regardless of the MRSA subset.

Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models

“…In our study, even against isolates with decreased susceptibility to vancomycin, daptomycin, or linezolid, only 10 isolates (2.7%) required telavancin at Ն0.25 g/ml to inhibit growth. Similarly, Mendes and colleagues (5,16) recently demonstrated that out of 7,264 MRSA isolates, 7,242 (99.7%) were inhibited at 0.0625 g/ml telavancin. The second of their studies indicated that even among MRSA with vancomycin MICs of 2 to 4 g/ml and daptomycin MICs of 1 to 2 g/ml, 100% of isolates were inhibited at 0.125 g/ml, making every isolate sus- ceptible by the current CLSI breakpoint (5, 10).…”

“…Telavancin also demonstrates activity against daptomycinnonsusceptible (DNS) S. aureus isolates, making it a valuable tool against these periodically reported strains (3,4). Recent surveillance data indicate 100% susceptibility among Ͼ9,500 S. aureus strains from 28 hospitals in the United States, with demonstrated MIC 50/90 of 0.03/0.06 g/ml (5). In this study, telavancin possessed MICs that were 8-fold and 32-fold less than those for daptomycin and vancomycin, respectively.…”

Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience

“…The recent in vitro activity of TLV from two large surveillance programmes CANWARD and 2011 is summarized in Tables 3 and 4. The efficacy of TLV against S. aureus isolates worldwide, regardless of methicillin susceptibility, was studied in the 2011-2013 SENTRY Antimicrobial Surveillance Program [Mendes et al 2015c], where isolates were tested for susceptibility by broth microdilution following Clinical and Laboratory Standards Institute (CLSI) guidelines [Ross et al 2014]. All S. aureus isolates were inhibited at a concentration <⩽ 0.12 μg/ml, with MIC 50 and MIC 90 values of 0.03 μg/ml and 0.06 μg/ml.…”

Telavancin Activity Against a Global Collection of Staphylococcus aureus Clinical Isolates (2013–2015)

“…The sustained potency of telavancin versus S. aureus strains collected in Europe from 2007 to 2008 [15] and in the United States from 2011 to 2013 [16] has been documented. The objective of the present study was to expand on the studies of Mendes et al [15,16] by including 22,406 S. aureus clinical isolates from 77 US medical centers; 2 Canadian medical centers; and the rest of the world (ROW) with 39 medical centers in 19 European countries/regions, 10 medical centers in 4 Latin American countries, and 19 Asian-Pacific medical centers in 9 countries for the years 2013 to 2015.…”

“…The objective of the present study was to expand on the studies of Mendes et al [15,16] by including 22,406 S. aureus clinical isolates from 77 US medical centers; 2 Canadian medical centers; and the rest of the world (ROW) with 39 medical centers in 19 European countries/regions, 10 medical centers in 4 Latin American countries, and 19 Asian-Pacific medical centers in 9 countries for the years 2013 to 2015. All testing was performed using the revised CLSI method with the new quality control (QC) MIC ranges and interpretive criteria [17,18].…”